EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals shareholders lost nearly 67% of their share value in a single session after the Phase 3 LUGANO topline readout. Levi & Korsinsky is investigating the losses on behalf of EYPT investors.

NEW YORK--(BUSINESS WIRE)--Roughly seven out of every ten dollars invested in EyePoint Pharmaceuticals (NASDAQ: EYPT) common stock was wiped out when shares fell nearly 67% following the Company's disclosure that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUGANO wet AMD trial. If you held EYPT shares through that decline, you are encouraged to have your EYPT losses reviewed now. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

The prespecified primary measure was change in best-corrected visual acuity versus on-label aflibercept. In the full LUGANO dataset, that endpoint was not met. The Company disclosed favorable secondary results, including a reported 42% reduction in treatment burden, and significantly focused on an ad hoc analysis excluding a 4% asymmetric patient cohort. The prespecified analysis remained a failure.

For shareholders, the loss was concentrated and immediate: a single readout, one trading session, approximately 70% of market value gone. Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT investors who suffered losses.

EyePoint investors who lost money are encouraged to submit your EYPT loss information here or call [phone].

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the EYPT Investigation

Q: How much did EYPT stock drop? A: When the market opened, EYPT shares were down $10.69, or approximately 72.47%, following the EyePoint’s release of topline results in the Phase 3 LUGANO wet AMD trial for DURAVYU. By end of day the drop had settled to a loss of around $9.88, or about 67%. Investors who purchased shares and suffered losses may be eligible to seek a recovery.

Q: Who is eligible to participate in the EYPT investigation? A: Investors who purchased EYPT stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: Who is conducting the EYPT investigation? A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased EYPT securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: What do EYPT investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my EYPT shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought EYPT and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: What if my EYPT losses are small -- is it still worth contacting a lawyer? A: Yes. There is no minimum loss amount required to participate in the investigation.

Attorney Advertising. Prior results do not guarantee similar outcomes.